Acquired Company

Sanofi completed acquisition of Kadmon Holdings, Inc. on 11/9/2021 for $9.50 per share in cash, representing an equity value of approximately $1.9 billion.

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. Show more

450 E 29th St, New York, 10016-8367, US

kadmon.com

Pharmaceutical Preparation Manufacturing

Manufacturing

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$9.50

Open

$9.50

Volume

1,052

Day Range

$9.50 - $9.50

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

0.00%

Institutional Own.

0.00%

Qtr Updated

03/31/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CLOVIQUE™ (Trientine Hydrochloride Capsules, USP) Details Wilson's disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.